Improved glycaemia in patients using the hybrid-closed-loop system MiniMed 670G (MM670G) has been demonstrated in clinical trials, but only limited real-world data is available yet. The aim of the present study was to analyse glycaemic control after the transition to the new MM670G and to compare it to the preceding treatment.
This was an 8-month analysis of 25 patients. A structured training program was set up for the transition to MM670G. CGM data were downloaded from the proprietary manufacturer’s software, analyzed with the Glyculator-2 script and compared to pre-transition CGM-data (30-day periods) if available.
Average operation time of CGM-sensor after transition to MM670G was 78%, and mean time in auto mode was 75%. HbA1c was 6.9±1.1%, mean glucose 8.2±0.8mmol/L, CV 31.4±5.8%, time in range (TIR, 3.9-10mmol/L) 76.1±11.6%, time > 10mmol/L 21.6±11.5% and time < 3.9mmol/L 2.3±2.2%, respectively. HbA1c significantly decreased using MM670G (7.4±1.5% vs 6.9±1.1%, p=0.002). Paired CGM data before and after transition to MM670G was available for 14 patients (all prior MM640G users). TIR was higher after change to MM670G (77.4±11.7% vs 70.0±14.5%, p=0.024), whereas time > 10.0mmol/L was lower (19.6±11.3% vs 26.4±15.3%, p=0.013). Coefficient of variation [CV] and interday-variability (MODD) were lower under MM670G compared to the preceding treatment (CV 32.7±6.2% vs 35.6±6.2%, p=0.013; MODD 2.7±0.8 vs 3.2±1.1mmol/L, p=0.04; respectively).
After switching to the new MM670G system, glycaemic control significantly improved in an already well-controlled cohort of diabetic patients. This improvement is reflected in particular by a higher time in range, decreased HbA1c and reduced glycemic variability.